CDKL5: a promising new therapeutic target for acute kidney injury?

Am J Physiol Renal Physiol

Division of Nephrology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.

Published: November 2020

Download full-text PDF

Source
http://dx.doi.org/10.1152/ajprenal.00535.2020DOI Listing

Publication Analysis

Top Keywords

cdkl5 promising
4
promising therapeutic
4
therapeutic target
4
target acute
4
acute kidney
4
kidney injury?
4
cdkl5
1
therapeutic
1
target
1
acute
1

Similar Publications

Article Synopsis
  • CDKL5 deficiency disorder (CDD) is a rare condition caused by genetic variants in the CDKL5 gene that lead to issues with neuronal development and function, particularly impacting epilepsy.
  • Research using patient-derived induced pluripotent stem cells aimed to understand how these variants affect neurons, showing that while some aspects like neurite length appeared similar to controls, organoid-derived neurons exhibited increased network activity and excitability.
  • The findings suggest that differences in neuronal behavior and gene expression are specific to excitatory cortical neurons, highlighting the potential for developing targeted therapies for CDD by exploring the molecular mechanisms behind early neuronal hyperexcitability.
View Article and Find Full Text PDF

Cannabinoids and Genetic Epilepsy Models: A Review with Focus on CDKL5 Deficiency Disorder.

Int J Mol Sci

October 2024

Brain and Mitochondrial Research Group, Murdoch Children's Research Institute, Royal Children's Hospital, Melbourne, VIC 3052, Australia.

Article Synopsis
  • Pediatric genetic epilepsies, including CDKL5 Deficiency Disorder (CDD), are severe and challenging, with many young patients experiencing frequent seizures that impede development and quality of life.
  • Current antiseizure medications often fail, prompting exploration into the therapeutic effects of cannabinoids like cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC), particularly for drug-resistant conditions.
  • Despite promising results for other genetic epilepsies, research specifically targeting CDD is scarce and primarily anecdotal; using advanced models like patient-derived neurons and brain organoids could provide better insights into cannabinoid efficacy and mechanisms for potential treatment options.
View Article and Find Full Text PDF

Objectives: This study aims to determine the current state of CDD diagnosis and epilepsy treatment in an upper-middle-income country.

Methods: Forty-seven families of the Brazilian CDD Association were invited to participate in an online survey to gather information about the diagnosis and treatment of epilepsy.

Results: Forty-three families (91.

View Article and Find Full Text PDF

Drug repurposing in Rett and Rett-like syndromes: a promising yet underrated opportunity?

Front Med (Lausanne)

July 2024

Department of Pediatrics, Emma Children's Hospital, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam UMC Location University of Amsterdam, Amsterdam, Netherlands.

Rett syndrome (RTT) and Rett-like syndromes [i.e., CDKL5 deficiency disorder (CDD) and FOXG1-syndrome] represent rare yet profoundly impactful neurodevelopmental disorders (NDDs).

View Article and Find Full Text PDF

Chlamydomonas reinhardtii is an important model organism for the study of many cellular processes, and protein tagging is an increasingly indispensable tool for these studies. To circumvent the disadvantages of conventional approaches in creating a tagged cell line, which involve transforming either a wild-type or null-mutant cell line with an exogenous DNA construct that inserts randomly into the genome, we developed a strategy to tag the endogenous gene in situ. The strategy utilizes TIM, a CRISPR/Cas9-based method for targeted insertional mutagenesis in C.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!